DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy (NCT07472517)
DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Who can join: Review the eligibility criteria below.
Location: Infirmary Cancer Care — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (245 Sites)
Showing the first 25 of 245 sites.
- Infirmary Cancer Care — Mobile, Alabama
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Bioresearch Partner - Hialeah Hospital — Hialeah, Florida
- Emory University — Atlanta, Georgia
- Norton Cancer Institute, Downtown — Louisville, Kentucky
- Pikeville Medical Center — Pikeville, Kentucky
- Epic Medical Research - Monroe — Monroe, Louisiana
- Ochsner Medical Center — New Orleans, Louisiana
- Epic Medical Research - Shreveport — Shreveport, Louisiana
- University of Maryland School of Medicine — Baltimore, Maryland
- Veterans Affairs Ann Arbor Healthcare System — Ann Arbor, Michigan
- HCA MidAmerica Division, Inc. — Kansas City, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- Cape Fear Valley Cancer Center — Fayetteville, North Carolina
- AHN Cancer Institute - Allegheny General — Pittsburgh, Pennsylvania
- Baptist Cancer Center - Memphis — Memphis, Tennessee
- University of Wisconsin — Madison, Wisconsin
- Hospital Britanico de Buenos Aires — CABA,
- Clinica Adventista Belgrano — CABA,
- Clinica Privada Independencia — Munro,
- Sanatorio Allende S.A. — Nueva Córdoba,
- Sanatorio Parque S.A. — Rosario,
- Prince of Wales Hospital-Randwick-66496 — Randwick, New South Wales
- Cancer Research South Australia — Adelaide, South Australia
- Ballarat Regional Integrated Cancer Centre — Ballarat, Victoria
📞 Contact the Study Coordinator
Phone: (800) 243-0127
Email: clintriage.rdg@boehringer-ingelheim.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer (SCLC)
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Mobile, Alabama
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Los Angeles, California
- Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Fayetteville, Arkansas
- Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer — Chicago, Illinois
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — Duarte, California
Explore by condition: All Small Cell Lung Cancer (SCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.